ABSTRACT
Riboswitches recently emerged as possible targets for the development of alternative antimicrobial approaches. Guanine-sensing riboswitches in the bacterial pathogen Clostridioides difficile (formerly known as Clostridium difficile) constitute potential targets based on their involvement in the regulation of basal metabolic control of purine compounds. In this study, we deciphered the structure-activity relationship of several guanine derivatives on the guanine riboswitch and determined their antimicrobial activity. We describe the synthesis of purine analogs modified in ring B as well as positions 2 and 6. Their biological activity was determined by measuring their affinity for the C. difficile guanine riboswitch and their inhibitory effect on bacterial growth, including a counter-screen to discriminate against riboswitch-independent antibacterial effects. Altogether, our results suggest that improvements in riboswitch binding affinity in vitro do not necessarily translate into improved antibacterial activity in bacteria, despite the fact that some structure-activity relationship was observed at least with respect to binding affinity.
Subject(s)
Anti-Bacterial Agents/pharmacology , Clostridioides difficile/drug effects , Guanine/antagonists & inhibitors , Purines/pharmacology , Riboswitch/drug effects , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Clostridioides difficile/growth & development , Clostridioides difficile/metabolism , Dose-Response Relationship, Drug , Guanine/metabolism , Microbial Sensitivity Tests , Molecular Structure , Purines/chemical synthesis , Purines/chemistry , Structure-Activity RelationshipABSTRACT
There are limited therapeutic options to treat infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The lipoglycopeptide oritavancin exhibits in vitro activity against this pathogen, although its utility against infections caused by VREfm has not been clinically established. In this study, the pharmacodynamic activity of free-drug levels associated with 12 mg/kg/day of daptomycin and a single 1,200-mg dose of oritavancin were determined against three VanA VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model.
Subject(s)
Anti-Bacterial Agents/pharmacology , Enterococcus faecium/drug effects , Glycopeptides/pharmacology , Glycopeptides/pharmacokinetics , Gram-Positive Bacterial Infections/drug therapy , Vancomycin-Resistant Enterococci/drug effects , Anti-Bacterial Agents/pharmacokinetics , Daptomycin/pharmacokinetics , Daptomycin/pharmacology , Enterococcus faecium/isolation & purification , Humans , Lipoglycopeptides , Microbial Sensitivity Tests , Vancomycin Resistance/physiology , Vancomycin-Resistant Enterococci/isolation & purificationABSTRACT
Antibacterial agents that kill nondividing bacteria may be of utility in treating persistent infections. Oritavancin and dalbavancin are bactericidal lipoglycopeptides that are approved for acute bacterial skin and skin structure infections in adults caused by susceptible Gram-positive pathogens. Using time-kill methodology, we demonstrate that oritavancin exerts bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates that are maintained in a nondividing state in vitro, whereas dalbavancin and the glycopeptide vancomycin do not.
Subject(s)
Anti-Bacterial Agents/pharmacology , Glycopeptides/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Teicoplanin/analogs & derivatives , Vancomycin/pharmacology , Lipoglycopeptides , Microbial Sensitivity Tests , Teicoplanin/pharmacologyABSTRACT
Pseudomonas aeruginosa and Staphylococcus aureus are the most prevalent pathogens in airway infections of cystic fibrosis (CF) patients. We studied how these pathogens coexist and interact with each other. Clinical isolates of both species were retrieved from adult CF patients. Culture supernatants from 63 P. aeruginosa isolates triggered a wide range of biofilm-stimulatory activities when added to the culture of a control S. aureus strain. The extent of biofilm formation by S. aureus was positively correlated to the levels of the 2-alkyl-4-(1H)-quinolones (AQs) Pseudomonas Quinolone Signal (PQS) and 2-heptyl-4-hydroxy quinoline N-oxide (HQNO) produced by the P. aeruginosa isolates. Supernatants from P. aeruginosa isogenic mutants deficient in PQS and HQNO production stimulated significantly less biofilm formation by S. aureus than that seen with the parental strain PA14. When studying co-isolated pairs of P. aeruginosa and S. aureus retrieved from patients showing both pathogens, P. aeruginosa supernatants stimulated less biofilm production by the S. aureus counterparts compared to that observed using the control S. aureus strain. Accordingly, some P. aeruginosa isolates produced low levels of exoproducts and also some of the clinical S. aureus isolates were not stimulated by their co-isolates or by PA14 despite adequate production of HQNO. This suggests that colonization of the CF lungs promotes some type of strain selection, or that co-existence requires specific adaptations by either or both pathogens. Results provide insights on bacterial interactions in CF.
